1. Kerr JF, Harmon BV. Definition and incidence of apoptosis: an historical perspective. Apoptosis. 1991;3:5–29.
2. Rai KR, Moore J, Wu J, Novick SC, O’Brien SM. Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia (CLL) on survival in patients who achieve CR/nPR: five-year follow-up from a randomized phase III study. J Clin Oncol. 2008;26(15):7008.
3. Abou-Nassar K, Brown JR. Novel agents for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2010;8(12):886–95.
4. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, et al. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut. 2005;54(9):1298–308.
5. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al. Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996;2(9):985–91.